
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein... Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. Its lead product candidate is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people who have received organ transplants. 더 보기
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0.0301 | 0.0301 | 0.0301 | 0 | 0 | CS |
4 | -0.1316 | -81.3852813853 | 0.1617 | 0.1845 | 0.0301 | 1263149 | 0.07710683 | CS |
12 | -0.1125 | -78.8920056101 | 0.1426 | 0.257406 | 0.0301 | 2709288 | 0.16548883 | CS |
26 | -0.2499 | -89.25 | 0.28 | 0.3388 | 0.0301 | 1719076 | 0.18243799 | CS |
52 | -0.6499 | -95.5735294118 | 0.68 | 1.31 | 0.0301 | 1015258 | 0.23014314 | CS |
156 | -2.7999 | -98.9363957597 | 2.83 | 5.75 | 0.0301 | 444437 | 0.72626961 | CS |
260 | -16.7299 | -99.8204057279 | 16.76 | 18.24 | 0.0301 | 404310 | 2.02738419 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관